New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation
Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation PEDIATRIC TRANSPLANTATION Marktel, S., Napolitano, S., Zino, E., Cappelli, B., Chiesa, R., Poli, F., Crocchiolo, R., Ronchi, P., Rossini, S., Ciceri, F., Roncarolo, M. G., Fleischhauer, K. 2010; 14 (3): 393-401Abstract
Immune-mediated refractoriness to platelet transfusion is a major problem in patients undergoing HSCT. In a cohort of 50 pediatric patients affected by beta thalassemia coming from Middle East countries, we experienced a high incidence of refractoriness because of anti-HLA antibodies during post-HSCT aplasia. In a risk factors analysis, factors predicting a negative transfusion outcome were presence of spleen and the number of anti-HLA antibodies. We adopted a policy to select platelet donors by avoiding HLA antigens against which the patient had specific antibodies. Transfusion of dedicated units resulted in 26% refractoriness compared to 74% to random units (p < 0.0001). When dedicated transfusions were used, the presence of spleen did not influence transfusion outcome. Analyzing transfusion outcome depending on the degree of HLA match and ABO compatibility, 76% successful transfusions were obtained with HLA-matched- ABO compatible followed by 67% in HLA-1mismatch- ABO compatible or HLA-matched- ABO incompatible and by 46% in HLA-1mismatch- ABO incompatible. In conclusion, we provide evidence that the selection of platelet donors according to patient characteristics, anti-HLA antibodies and ABO matching, is successful in reducing platelet refractoriness in heavily alloimmunized thalassemia patients undergoing transplantation.
View details for DOI 10.1111/j.1399-3046.2009.01282.x
View details for Web of Science ID 000276495900021
View details for PubMedID 20070557